<DOC>
	<DOC>NCT00737100</DOC>
	<brief_summary>This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations</brief_summary>
	<brief_title>Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: 1. Male or female patients 2. Diagnosis of Cystic Fibrosis (positive sweat chloride test or two identifiable mutations) 3. Prebronchodilator FEV1 greater/equal 25% of predicted values Exclusion criteria: 1. Significant history of allergy/hypersensitivity 2. Hypersensitivity to study drug 3. Participation in another trial 4. Female patients who are pregnant or lactating 5. Female patients of childbearing potential 6. Patients who have started a new medication for CF within 4 weeks of screening 7. Patients with known substance abuse 8. Clinically significant disease other than CF</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>